Accure Receives CE Mark Approval for First-Ever 1726nm Laser Platform to treat Acne

Groundbreaking platform combines novel laser wavelength with fully integrated tissue temperature monitoring and control systems to deliver a paradigm-shifting non-systemic solution for acne sufferers....

Learn More

Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib)

Collaboration will focus on development of a companion diagnostic (CDx) for Vitrakvi®, the first-in-class tyrosine kinase (TRK) inhibitor approved in the U.S. and Europe for adult pediatric patients w...

Learn More

Tolmar Pharmaceuticals Receives FDA Approval

FDA Approves FENSOLVI® (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty Fensolvi is the only six-month, subcutaneously administered leuprolide acet...

Learn More

Global Plasma Leaders Collaborate to Accelerate Development of Potential Covid-19 Hyperimmune Therapy

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19. Learn more in the press release.

Learn More

MBio to Seek FDA Approval for LightDeck® Platform

Future Use in Outbreak Management Expected, via DARPA Partnership Boulder, CO, April 6, 2020 – MBio Diagnostics today announced an expanded scope contract with the US Defense Advanced Research Project...

Learn More

Amgen and Adaptive Biotechnologies Announce Strategic Partnership to Develop a Therapeutic to Prevent or Treat COVID-19

Adaptive Extends Immune Medicine Platform to Discover Therapeutic Antibodies From Recovered COVID-19 Patients Amgen Will Leverage Genetics, Immunology, Antibody Engineering and Manufacturing Capabilit...

Learn More

Aktivax, Inc. has been awarded a $16 million contract from the Biomedical Advanced Research and Development Authority (BARDA)

FOR IMMEDIATE RELEASE [BROOMFIELD, CO – 31 MARCH 2020] Shortly after receiving a $24.5 million project from the Department of Defense (DOD) to develop a scopolamine auto-injector, Aktivax, Inc. has be...

Learn More

Flagship Biosciences Hires New Vice President of Clinical Diagnostics

Westminster, CO, March 31, 2020 -- Flagship Biosciences, providers of expert tissue data insights, today announced that Geoff Metcalf, MBA, PMP, will join its executive team as Vice President Clinical...

Learn More

SOPHiA GENETICS and Paragon Genomics Join Forces Against COVID-19 Coronavirus Pandemic

Lausanne, Switzerland, and Boston, United States – March 26, 2020 SOPHiA GENETICS, leader in Data-Driven Medicine, today announced that it is entering the fight against the COVID-19 coronavirus by ext...

Learn More

Aktivax, Inc. Awarded a $24.5M US Government Project

FOR IMMEDIATE RELEASE [BROOMFIELD, MARCH 23, 2020] Aktivax, Inc. has been awarded a $24.5 million US government project to develop an autoinjector treatment for exposure to nerve agents. The award is...

Learn More